display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - all population
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CheckMate 067 ...
nivolumab followed by ipilimumab CheckMate 064

Study type: